Zifo Launches AI Antibody Engineering App on Snowflake

August 15, 2025
Zifo has introduced its AI-powered Antibody Engineering application on the Snowflake Marketplace, designed to accelerate biologics and drug discovery by optimizing therapeutic antibodies.

Zifo Technologies has launched its AI-powered Antibody Engineering application on the Snowflake Marketplace, announced in a press release. This cloud-native GenAI platform is designed to accelerate the design and optimization of therapeutic antibodies, potentially shortening the timeline for new drug discovery.

The application supports three open-source models—ProtGPT2, ESM, and RoBERTa—allowing users to benchmark and tailor models within a single environment. This flexibility aims to improve the hit rate for high-affinity therapeutic antibodies by integrating state-of-the-art AI into a seamless workflow.

Leveraging Snowflake's platform, the app provides a no-code interface for scientists and bioinformaticians to fine-tune protein language models on proprietary datasets securely. The platform facilitates the entire discovery pipeline, from generating novel antibody sequences to predicting their 3D structures and analyzing key regions.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more